Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05282004 · ClinicalTrials.gov registry record · Phase 3
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit
A Phase 3 study of Neovascular Age-related Macular Degeneration (nAMD), sponsored by Sandoz.
- Completed
- Registry status
- Phase 3
- Development phase
- 36
- Enrollment target
- 5
- Study locations
NCT05282004: Completed Phase 3 study of Neovascular Age-related Macular Degeneration (nAMD), sponsored by Sandoz.
NCT05282004 is a Phase 3 study of Neovascular Age-related Macular Degeneration (nAMD) that has completed, run by Sandoz. The registered enrollment target is 36 participants, below the 204-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target (82% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05282004, a Phase 3 study of Neovascular Age-related Macular Degeneration (nAMD), has completed, sponsored by Sandoz.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 36 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a single-arm, open-label study where all patients will receive a single injection of SOK583A1 (40 mg/mL) provided in a vial kit at Baseline. The total study duration for the individual participant is approximately 31 days.
Primary Outcome
Number of participants with ocular treatment emergent adverse events were reported.
Conditions Studied
Interventions
- DRUG SOK583A1
Study Locations (5)
California
- Sandoz Investigational Site - Poway
Georgia
- Sandoz Investigational Site - Marietta
Illinois
- Sandoz Investigational Site - Oak Forest
New York
- Sandoz Investigational Site - Liverpool
Virginia
- Sandoz Investigational Site - Lynchburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-05-16 |
| Est. Completion | 2022-09-07 |
| Phase | Phase 3 |
What the finished NCT05282004 record still lists
NCT05282004 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 204-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Neovascular Age-related Macular Degeneration (nAMD) appearing as the primary indexed condition, and to 1 intervention - of which SOK583A1 is the first listed.
NCT05282004 lists 5 locations in 5 states (California, Georgia, Illinois).
Frequently Asked Questions
What is clinical trial NCT05282004 about?
NCT05282004 is a clinical study titled "Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit". This is a single-arm, open-label study where all patients will receive a single injection of SOK583A1 (40 mg/mL) provided in a vial kit at Baseline. The total study duration for the individual participant is approximately 31 days.
What is the current status of trial NCT05282004?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 36 participants. The study started on 2022-05-16. Estimated completion is 2022-09-07.
What conditions does trial NCT05282004 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration (nAMD).
What interventions are being tested in trial NCT05282004?
The interventions under investigation include: SOK583A1 (DRUG).
Who is sponsoring clinical trial NCT05282004?
This trial is sponsored by Sandoz, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05282004 being conducted?
This trial has 5 study locations across California, Georgia, Illinois, New York, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration (nAMD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05282004's enrollment target sits among peer trials
36 8th of 9 higher than 2 of 9 other Neovascular Age-related Macular Degeneration (nAMD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neovascular Age-related Macular Degeneration (nAMD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
RECRUITING · Phase 3
-
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
RECRUITING · Phase 3
-
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
RECRUITING · Phase 3
-
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe
COMPLETED · Phase 3
-
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
RECRUITING · Phase 1
-
Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI